435 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast PVI, PeerView Institute for Medical Education

    • Science
    • 4.6 • 9 Ratings

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    James R. Gavin III, MD, PhD - The Contemporary Use of GLP-1 RAs to Individualize Therapy in T2DM: Candid Conversations on Glycemic and Nonglycemic Effects

    James R. Gavin III, MD, PhD - The Contemporary Use of GLP-1 RAs to Individualize Therapy in T2DM: Candid Conversations on Glycemic and Nonglycemic Effects

    Go online to PeerView.com/QAM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a preeminent drug class for treating type 2 diabetes mellitus (T2DM). Mounting evidence from cardiovascular outcomes trials elevated these agents’ position in clinical guidelines because of their ability to reduce cardiovascular and renal risks, while also improving glycemic control without the burdens of hypoglycemia or weight gain. In this activity, based on a recent live web broadcast, Dr. James R. Gavin III, welcomes special guests Dr. Jens Juul Holst and Davida F. Kruger for candid conversations about the science behind GLP-1 RAs and its translation into patient-centered approaches for managing T2DM. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for the prioritization of GLP-1 RAs in current clinical guidelines for patients with T2DM, including in patients with cardiovascular or renal disease, Compare and contrast GLP-1 RAs in terms of mechanism of action, safety, efficacy, mode of administration, and glycemic and nonglycemic effects, Engage in shared decision-making with patients with T2DM to individualize therapy with GLP-1 RAs, overcome administration barriers, and improve adherence, Incorporate GLP-1 RAs into evidence-based, individualized treatment regimens as appropriate for patients with T2DM.

    • 1 hr 20 min
    Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

    Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

    Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

    • 1 hr
    "Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

    "Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

    Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.

    • 19 min
    Deborah K. Armstrong, MD - The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitors Into Clinical Practice

    Deborah K. Armstrong, MD - The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitors Into Clinical Practice

    Go online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors and are being investigated in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Join PeerView and the National Ovarian Cancer Coalition for an educational activity that will combine a review of key data on PARP inhibitors with practical expert guidance on integrating these agents into clinical practice. Using PeerView’s unique “Candid Conversations & Clinical Consults” format, this activity will provide participants with multiple perspectives, including those from clinicians in academic and community settings, patients, and advocates; opportunities to reflect on how treatment advances will affect patient care; and a venue for having oncology experts answer their questions on using PARP inhibitors in a variety of settings. With case patients drawn from practice serving as the framework for activity, the expert faculty panel will delve into critical concepts, including genetic testing guidelines, clinical trial enrollment, and recognizing and managing adverse events associated with PARP inhibitors, and engage in interactive discussions that will bring clinical decision points to life. Upon completion of this accredited CE activity, participants should be better able to: Assess the rationale for and latest clinical evidence on available and emerging PARP inhibitor agents and combinations for patients with primary and recurrent advanced ovarian cancer, Apply current clinical practice recommendations for germline and tumor genetic testing in patients with advanced ovarian cancer, Integrate PARP inhibitors into personalized management plans, including in the context of clinical trials, for eligible patients with primary and recurrent advanced ovarian cancer, Employ appropriate strategies to manage the unique safety issues related to the use of PARP inhibitors, including with long-term use associated with maintenance settings, in patients with advanced ovarian cancer.

    • 1 hr 29 min
    Christopher D. Still, DO, FACP, FTOS / Alan C. Wittgrove, MD, FASMBS, FACS - Going With Your Gut: Targeting Long-Term Weight Loss With Current and Emerging Incretin-Based Pharmacotherapy

    Christopher D. Still, DO, FACP, FTOS / Alan C. Wittgrove, MD, FASMBS, FACS - Going With Your Gut: Targeting Long-Term Weight Loss With Current and Emerging Incretin-Based Pharmacotherapy

    Go online to PeerView.com/FQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, which is based on a recent live web broadcast, two obesity experts discuss weight-loss pharmacotherapy in the context of bariatric surgery as part of practical, case-centered sessions, designed to mimic the treatment considerations faced in real-world practice and illustrate how incretin-based agents can be used to individualize long-term obesity management and improve patient outcomes. Upon completion of this accredited CE activity, participants should be better able to: Recognize the roles of treatment options used adjunct to lifestyle interventions, particularly weight-loss pharmacotherapy and surgery, in addressing obesity pathophysiology, including metabolic adaptation, Assess the available evidence on current and emerging options in incretin-based weight-loss pharmacotherapies, including long-term efficacy and safety data, Integrate incretin-based pharmacotherapy into individualized, evidence-based treatment plans for long-term obesity management.

    • 57 min
    Sumanta Kumar Pal, MD - New Data and Clinical Context: An Update on Renal Cell Carcinoma Care in Early Through Advanced Disease

    Sumanta Kumar Pal, MD - New Data and Clinical Context: An Update on Renal Cell Carcinoma Care in Early Through Advanced Disease

    Go online to PeerView.com/YFW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses new evidence from ASCO 2021 on the continuing integration of immunotherapy, targeted agents, and novel therapeutics across a wide range of renal cell carcinoma settings. Upon completion of this activity, participants should be better able to: Assess recent efficacy and safety data on new treatment approaches, including targeted TKIs, immuno-oncology (IO) agents, and novel combination approaches, for advanced renal cell carcinoma (RCC), Integrate recent clinical research findings on validated TKI and IO-based options into the development of individualized treatment plans for patients with newly diagnosed and previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for RCC patients in different disease and treatment settings, Implement practical strategies to mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.

    • 29 min

Customer Reviews

4.6 out of 5
9 Ratings

9 Ratings

Albeamy ,

Fix titles!

Your titles are so long I can't see what the podcast is about without playing it and watching the long title scroll along my screen. That makes your podcasts too difficult to access to be useful.

Top Podcasts In Science

Listeners Also Subscribed To